Advertisement

Topics

Astellas scoops up Universal Cells for $102.5m

04:37 EST 15 Feb 2018 | Pharmafile

Astellas Pharma had only signed an exclusive licensing deal with Universal Cells back in October for the co-development of a particular drug candidate utilising the latter company’s technology, four months later Astellas has returned to buyout the company.

Clearly, Astellas liked what it saw during the exploratory deal to use Universal Cells’ proprietary Universal Donor Cell technology – this sees the biotech able to create cell therapy products that do not require Human Leukocyte antigen matching.

read more

Original Article: Astellas scoops up Universal Cells for $102.5m

NEXT ARTICLE

More From BioPortfolio on "Astellas scoops up Universal Cells for $102.5m"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...